A Clinical and Biological Research of Combined Chinese and Western Medicine in the Treatment of PCOS

Aijun Sun315 enrolled

Overview

This study evaluates the effects and biological mechanisms of Dingkundan，Diane-35 and the combination of Dingkundan and Diane-35 in the treatment of polycystic syndrome(PCOS) in adults women. One third of participants will receive Dingkundan capsules, one third of participants will receive Diane-35 Pills, and the another third will receive Dingkundan capsules and Diane-35 in combination.

Dingkundan,Diane-35 each ameliorate PCOS, but they do so by different mechanisms. We generally treat PCOS patients without immediate fertility requirement by short-acting contraceptives,Diane-35 is one of the most commonly used drugs. Dingkundan consists of multiple chinese herbs including ginseng,Panax notoginseng,deer antlers,Carthamus tinctorius L.,Radix Paeoniae Alba,prepared Radix Rehmanniae,Angelica etc., which gains widespread application in the treatment of gynecological diseases. Based on the characteristics above, we try to explore its clinical application value in PCOS and its biological mechanisms.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

315

Conditions

PCOS

Interventions

DingkundanDRUG

Dingkundan 7g capsule by mouth, twice daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles

Dingkundan & Diane-35DRUG

Dingkundan 7g capsule by mouth, twice daily, and Diane-35 one pill by mouth, once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles

Diane-35DRUG

Diane-35 one pill by mouth,once daily, beginning on Day 5 of menstrual cycle for 21 consecutive days followed by a 7-day interval without medication; for three cycles

Eligibility

Sex: FEMALEMin age: 18 YearsMax age: 40 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Subject is a female between the age of 18 and 40. * Subject diagnosed as PCOS by the 2003 Rotterdam criteria. * Subject provides written informed consent. Exclusion Criteria: * Subject has other endocrine diseases,such as adrenal hyperplasias or tumor, androgen-secreting tumours, Cushing's syndrome,thyroid diseases and hyperprolactinemia. * Subject has received related medical or surgical treatment in the past 3 months. * Subject suffered from substance abuse or dependence(such as alcohol or drugs); * Subject is a heavy smoker(reaching or more than 20 cigarettes a day). * Subject is pregnant or lactating or within 1 year after delivery. * Subject has a severe systemic disease, such as cardiovascular system * Subject has a history of malignancy or radiotherapy. * Subject has an allergic history to the drugs used in the study. * Subject has mental disorder incapable of elementary cooperations. * Subject has participated in other clinical researches of medicine within 3 month prior to randomization.

Locations (1)

Lei Li

Beijing, China/Beiing, China

RECRUITING

Outcomes

Primary Outcomes

symptoms

PCOS symptoms

Time frame: 5 minutes

sex hormone levels changes

Time frame: 5 minutes

Secondary Outcomes

lipid metabolism

blood lipid profile

Time frame: 5 minutes

metabolites figure spectrum

metabolites figure spectrum to undermine the mechanism of Dingkundan and Diane-35 in the treatment of PCOS

Time frame: 5 minutes

Fasting insulin

Time frame: 5 minutes

glycosylated hemoglobin

Time frame: 5 minutes

fasting blood glucose

Time frame: 5 minutes

Central Contacts

Lei Li, MD

CONTACT

139-1198-8831 lileigh@163.com

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.